MedImmune

Particle Design using Spray Drying

Reinhard Vehring

MedImmune Inc., 319 North Bernardo Ave, Mountain View, CA 94043

Outline

- **Study of Particle Formation Mechanism**
  - Experimental Methods
    - Droplet Chain
    - Monodisperse Spray Dryer
  - Theoretical Approach
  - Results
- **Particle Design Examples**
- **Summary and Outlook**

Droplet Chain Technique





- Droplets do not influence gas phase
- Allows measurement of evaporation rates

Vehring, et al., AAAR Annual Conf., Atlanta, GA, 2004

MedImmune

Monodisperse, Monomorph Particles



Geometric diameter and density can be correlated with drying rate

Only small quantities can be produced (< 1mg/h)

MedImmune

Monodisperse Spray Dryer



- 1000 x higher production rates
- Gas phase conditions not constant
- No direct observation of evaporation process
- Online measurement of aerodynamic dry particle diameter

MedImmune

Particles from Monodisperse Spray Dryer



- Consistent morphology
- Density of main population can be determined

Analytical Description

Analytical model provides dimensionless numbers

Diffusion equation for normalized radial coordinate, $R=r/r_s$,

$$\frac{\partial c}{\partial t} = \frac{D}{r_s^2}\left(\frac{\partial^2 c}{\partial R^2} + \frac{2\partial c}{R\partial R}\right) + \frac{R\partial c\partial r_s}{r_s\partial R\partial t} , \qquad d^2(t) = d_0^2 - \kappa t$$

D: Diffusion coefficient, c: concentration, r_s: droplet radius, *d*: droplet diameter, κ: evaporationon rate.

.

Solution

$$c = c_m \frac{\exp\left(-0.5\mathrm{Pe}R^2\right)}{3\int_0^1 R^2 \exp\left(-0.5\mathrm{Pe}R^2\right)\mathrm{d}R} , \qquad \mathrm{Pe} = -\frac{r_s\partial r_s}{D\partial t} = \frac{\kappa}{8D}$$

where the concentration is expressed as a function of the average concentration in the droplet, c_m. Pe is the Peclet number.

After: Leong, K. H., *J. Aerosol Sci* **18**, 511, (1987)

MedImmune

Case 1: Large Molecules



Morphology and density change with drying rate

Glycoprotein, MW: 51 kDa, D: $6 \cdot 10^{-11}$ m^2/s (estimate)

MedImmune

Density Decreases with Increasing Pe-Number



Theory Predicts Surface Enrichment of Protein



Dry particle formation coincides with predicted high surface concentration of the protein.

MedImmune

Diffusion Controlled Particle Formation



Large Peclet Number Examples





Polystyrene nanoparticle (170 nm) suspension

Peptide formulation



Salmon Calcitonin



N. Tsapis et al. PNAS 99, 12001 (2002); H.-K. Chan et al, AAPS annual meeting, 2002;
Vehring, R. IBC 4th Annual Conference, Delivery Strategies for Proteins and Peptides, Boston, MA, 2004

MedImmune

Case 2: Small Molecules





Low Peclet Number (<2) and high solubility leads to solid particles with a density close to the pycnometer density (1.53 g/cm^3)

MedImmune

Small Molecules at High Peclet Numbers





Lactose particles, dried at high drying gas temperatures (200 °C inlet)

Peclet number range: 2-5

Saccharides can form hollow particles at high Peclet numbers

Elversson, J., et al. J. Pharm Sci, 92, 900 (2003)

MedImmune

Small Molecules

Low Solubility – High Surface Activity



Solubility: 8 mg/ml (25°C, pH7)

Surface Activity: 42 mN/m (sat, 25°C)

MW: 357.5 Da



Particles with very low density can be formed from small molecules

MedImmune

Small Molecules

Low Solubility – Low Surface Activity





Surface activity is not necessary for low particle density

Particle Formation Coincides with Supersaturation



Precipitation leads to sharp increase in Pe - number

Particle Formation with Early Phase Separation



Designing Structured Particles - Applications



- **Encapsulation**
- **Structural layers**

- **Improving physical stability**
- **Improving biological / chemical stability**
- **Improving powder / aerosol properties**
  - Flowability
  - Dispersibility
  - Density / Aerodynamic diameter
- **Improving delivery**
  - Solubility
  - Bioadhesion
  - Release

MedImmune

Encapsulation of a Model Molecule

100 % PVP K17



90 % PVP, 10 % Amino Acid



Amino acid solubility intentionally reduced by a co-solvent to achieve encapsulation

Vehring, et al., US 20050003004, WO/2005/000267

Surface Modification of an Antibody Therapeutic

IgG1 - Antibody



Encapsulated
with 37.5 % amino acid



Encapsulation improves dispersibility

MedImmune

Encapsulation Improves Physical Stability

56 % encapsulation excipient, 20 % saccharide, 20 % low Tg API, 4 % organic salt





Vehring, R. IBC 4th Annual Conf., Deliv. Strat. Proteins & Peptides, Boston, 2004

MedImmune

Structured Particle with Excellent Environmental Robustness



~ 20 °C above Tg !

Low Tg core
protected
by a high Tg shell

MedImmune

Summary and Outlook

- Particle formation can be understood in the context of component saturation and Peclet number
- Surface activity and other material properties may influence particle morphology
- Analysis of particle formation enables rational particle design of structured particles through formulation and process design
- Particle engineering achieves much improved particle properties, enabling new products and improving product performance
- More work is necessary to understand and control nanostructures and multiple functional layers
- Process technology and formulation science must work together

Acknowledgements

Willard R. Foss

Amgen Inc., Thousand Oaks, CA

Christopher I. Grainger

Kings College, London

David Lechuga-Ballesteros, Mei Chang Kuo, Danforth P. Miller

Nektar Therapeutics, San Carlos, CA

Solid State Formulation Group

MedImmune Inc., Mountain View, CA

James Ivey, Lisa Williams, Sandhya Buchanan, Yi Ao,
Luisa Yee, Emilie Pan, Rekha Rao

MedImmune